Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Capital Asset Advisory Services LLC

Capital Asset Advisory Services LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,075 shares of the medical research company’s stock after purchasing an additional 127 shares during the period. Capital Asset Advisory Services LLC’s holdings in Thermo Fisher Scientific were worth $3,232,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC purchased a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $26,000. Peterson Financial Group Inc. purchased a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $27,000. Missouri Trust & Investment Co purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at about $29,000. Endeavor Private Wealth Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at about $30,000. Finally, Decker Retirement Planning Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at about $43,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $558.12, for a total value of $5,581,200.00. Following the completion of the transaction, the chief executive officer now owns 33,608 shares of the company’s stock, valued at approximately $18,757,296.96. This trade represents a 22.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 34,850 shares of company stock worth $19,123,197 over the last quarter. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $575.21 on Monday. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The firm has a market capitalization of $220.02 billion, a PE ratio of 36.06, a P/E/G ratio of 3.82 and a beta of 0.76. The company’s 50 day simple moving average is $533.60 and its 200 day simple moving average is $569.58.

Thermo Fisher Scientific declared that its board has approved a share repurchase program on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 2% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were paid a dividend of $0.39 per share. The ex-dividend date was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TMO. Stephens began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price target on the stock. Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. TD Cowen increased their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Finally, Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $648.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.